Neuromyelitis optica (NMOSD): trials for referral
71 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
71 trials shown
Phase 22 sites
RecruitingUnited States
NCT06453694
Efgartigimod for the Treatment of Acute Optic Neuritis
Anastasia Vishnevetsky, MD, MPH
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 18 sites
RecruitingUnited States
NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT07804004
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
CRISPR Therapeutics
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT06561009
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Tianjin Medical University General Hospital
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingJapan
NCT07738952
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
Kyushu University
Registry updated 7 Oct 2026
Registry record: ClinicalTrials.govPhase 313 sites
RecruitingArgentina, China, France, United Kingdom, Italy, Mexico
NCT05199688
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Hoffmann-La Roche
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 43 sites
RecruitingGermany, United States
NCT07010302
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Massachusetts General Hospital
Registry updated 24 Sept 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT07685678
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
Zhongming Qiu
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT06620809
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Tongji Hospital
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 424 sites
Not yet recruitingFrance
NCT07818356
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
University Hospital, Toulouse
Registry updated 14 Sept 2026
Registry record: ClinicalTrials.govPhase 39 sites
RecruitingChina
NCT07557420
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc.
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07809724
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Peking University People's Hospital
Registry updated 9 Sept 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07573332
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
University of Texas Southwestern Medical Center
Registry updated 17 Jul 2026
Registry record: ClinicalTrials.govPhase 410 sites
Not yet recruitingChina
NCT07699770
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
Tang-Du Hospital
Registry updated 13 Jul 2026
Registry record: ClinicalTrials.govNo phase2 sites
By invitation onlyUnited States
NCT06374264
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
MedRhythms, Inc.
Registry updated 6 Jul 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT07676266
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
The Affiliated Hospital of Qingdao University
Registry updated 30 Jun 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07595965
Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
Corestemchemon, Inc.
Registry updated 19 May 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingChina
NCT07592754
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
Chinese PLA General Hospital
Registry updated 18 May 2026
Registry record: ClinicalTrials.govPhase 31 site
RecruitingChina
NCT07420296
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Tianjin Medical University General Hospital
Registry updated 14 May 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07526493
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Registry updated 12 May 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingIsrael
NCT07085676
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Polina Stepensky
Registry updated 6 May 2026
Registry record: ClinicalTrials.govPhase 2/351 sites
RecruitingChina
NCT06413654
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Shanghai Jiaolian Drug Research and Development Co., Ltd
Registry updated 5 May 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingChina
NCT07410039
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Chinese PLA General Hospital
Registry updated 12 Mar 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingChina
NCT07392528
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Registry updated 11 Feb 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT05504694
Ofatumumab in AQP4-IgG Seropositive NMOSD
Tang-Du Hospital
Registry updated 30 Jan 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07377305
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Tang-Du Hospital
Registry updated 29 Jan 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07341828
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Huashan Hospital
Registry updated 15 Jan 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingChina
NCT06939166
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Registry updated 15 Dec 2025
Registry record: ClinicalTrials.govPhase 219 sites
RecruitingArgentina, Brazil, Canada, Spain, France, United Kingdom
NCT05549258
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Amgen
Registry updated 5 Dec 2025
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07159893
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
First Affiliated Hospital of Wenzhou Medical University
Registry updated 8 Sept 2025
Registry record: ClinicalTrials.gov
The same sites as a list
- China30 open trials
- United States17 open trials
- France9 open trials
- Italy8 open trials
- United Kingdom4 open trials
- Germany4 open trials
- Argentina3 open trials
- Japan2 open trials
- Poland2 open trials
- Canada2 open trials
- South Korea2 open trials
- Türkiye1 open trial
- Mexico1 open trial
- Israel1 open trial
- Netherlands1 open trial
- Brazil1 open trial
- Spain1 open trial
- Sweden1 open trial
- Serbia1 open trial
- United Arab Emirates1 open trial
- Austria1 open trial
- Australia1 open trial
- Martinique1 open trial
- Greece1 open trial
- Switzerland1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
National Hospital for Neurology and Neurosurgery
London, United Kingdom
1 trial · 10 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
No registry change in the last 7 days.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 26 Aug 2026
Completed5 participants
2024-517176-38-00
lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder
Phase 1/2Ended 1 Aug 2026
Withdrawn before start0 participants
NCT05909943
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
Reason given: We are doing a clinical study of Baritinib in Neuromyelitis Optica Spectrum Disorders, similar to this one, so the study was withdrawn.
Phase 3Ended 3 Apr 2026
Stopped early178 participants
NCT03330418
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Reason given: Sponsor Strategic Priority Adjustment
No phaseEnded 26 Feb 2026
Stopped early3 participants
NCT07247292
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
Reason given: The decision is based on strategic deprioritization and is not related to any safety concerns.
Phase 2/3Ended 28 Nov 2025
Withdrawn before start0 participants
NCT03829566
Autologous Transplant To End NMO Spectrum Disorder
Reason given: Discontinued by Investigator
Phase 1Ended 30 Jul 2025
Completed9 participants
NCT05828212
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
Phase 1Ended 17 Jun 2025
Withdrawn before start0 participants
NCT06869278
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Reason given: Legend discontinues the development of the IMP.
No phaseEnded 3 Mar 2025
Phase 2Ended 15 Jan 2025
No phaseEnded 8 Dec 2024
Completed800 participants
NCT07164924
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
No phaseEnded 21 Nov 2024
Phase 3Ended 31 Oct 2024
Completed58 participants
NCT04201262
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
- Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. · Multiple sclerosis (Houndmills, Basingstoke, England), 2026
- Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results. · Neurology(R) neuroimmunology & neuroinflammation, 2026
Phase 2Ended 18 Jul 2024
Completed46 participants
NCT05551598
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
No phaseEnded 3 Jun 2024
Completed15 participants
NCT04629274
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO
Phase 3Ended 28 May 2024
Completed119 participants
NCT04660539
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1/2Ended 9 Apr 2024
Completed14 participants
NCT05154734
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
No phaseEnded 3 Apr 2024
Phase 2Ended 24 Feb 2024
Stopped early6 participants
NCT05356858
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
Reason given: Difficult in participant recruiting
No phaseEnded 31 Dec 2023
Withdrawn before start0 participants
NCT04131673
MS and NMOSD in African-Americans
Reason given: IRB closed
Phase 1Ended 25 Dec 2023
Completed15 participants
NCT04146285
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Not medical advice. fetched 9 Nov 2026